CURRENT
ISSUE
1724

The FDA has approved Alyftrek (Vertex), an oral fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators vanzacaftor, tezacaftor, and deutivacaftor, for once-daily treatment of cystic fibrosis (CF) in patients ≥6 years old who have at least one F508del mutation or another responsive mutation in the CFTR gene. This is the first approval for vanzacaftor and for deutivacaftor, a deuterated form of ivacaftor. Trikafta, a twice-daily oral fixed-dose combination of elexacaftor, tezacaftor, and ivacaftor, is FDA-approved for the same indication in patients ≥2 years old. Continue reading

Coming Soon
Palopegteriparatide (Yorvipath) for Hypoparathyroidism
Benzgalantamine (Zunveyl) for Alzheimer's Disease
Penmenvy: A Second Pentavalent Meningococcal Vaccine
Label Changes for Testosterone Products